List view / Grid view
A new study has highlighted two broadly neutralising antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations.
Complexities related to the development of stable cell lines and increased risk of contamination in upstream and downstream processes, have led many developers to seek critically needed expertise from external partners. Soojin Han, Samsung Biologics America, offers an expert look at the various challenges and tactics that can be applied.
Using a machine learning model, scientists could predict not only the virus an antibody will attack, but which features on the pathogen the antibody binds to.
A monoclonal antibody (mAb) developed by IGM Biosciences to combat COVID-19 has shown success in pre-clinical studies and has now moved into Phase I trials. In this Q&A, Dr Chris Takimoto, Chief Medical Officer at IGM Biosciences, explains how this biotherapeutic works to prevent and treat SARS-CoV-2 infection.
Protecting against conditions that appear in older generations is increasingly becoming a focus of the medical industry. In this article, Dr Andrea Pfeifer, CEO and Director of AC Immune, discusses the current landscape of vaccine development for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
This ebook includes articles about antibody-based therapies that could protect against cancer by utilising a patient's memory B cells. Also included is a piece on an intranasally-delivered monoclonal antibody treatment to potentially protect against SARS-CoV-2.
A new study has showed how a bioengineered RSV protein vaccine can induce a protective immune response in animal models.
Researchers at UC Davis Health have engineered an antibody that interferes with a critical cell mechanism to reduce transmission of the virus that causes COVID-19 in lab tests.
This ebook has features on the development of intranasally-delivered antibodies to combat SARS-CoV-2 and how the structure of a nanobody was determined using nuclear magnetic resonance methods.
Learn what sets Bethyl custom monoclonal antibodies quality and service apart and discover the top reasons why you should choose Forits Life Sciences for your next project.
A wide range of tools to support your immuno-oncology research and help redefine and develop tailored, life-changing immunotherapies to fight cancer.
The latest ebook from Sartorius takes an in-depth look at the technologies and techniques that have been integral to developing the antibody discovery workflow, featuring a host of expert articles, interviews and application notes.
With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe…
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
